help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gonzalez-Rey, E.
Right arrow Articles by Delgado, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gonzalez-Rey, E.
Right arrow Articles by Delgado, M.
(American Journal of Pathology. 2006;168:1179-1188.)
© 2006 American Society for Investigative Pathology

Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Autoimmune Encephalomyelitis

Down-Regulation of Inflammatory and Autoimmune Responses

Elena Gonzalez-Rey*, Amelia Fernandez-Martin*, Alejo Chorny*, Javier Martin*, David Pozo{dagger}, Doina Ganea{ddagger} and Mario Delgado*

From the Institute of Parasitology and Biomedicine,* Consejo Superior de Investigaciones Científicas, Granada, Spain; the Department of Biochemistry and Molecular Biology,{dagger} Medical School of Seville, Seville, Spain; and the Department of Biological Sciences,{ddagger} Rutgers University, Newark, New Jersey

Multiple sclerosis (MS) is a disabling inflammatory, autoimmune demyelinating disease of the central nervous system. Despite intensive investigation, the mechanisms of disease pathogenesis remain unclear, and curative therapies are unavailable for MS. The current study describes a possible new strategy for the treatment of MS, based on the administration of the vasoactive intestinal peptide (VIP), a well-known immunosuppressive neuropeptide. Treatment with VIP significantly reduced incidence and severity of experimental autoimmune encephalomyelitis (EAE), in a MS-related rodent model system. VIP suppressed EAE neuropathology by reducing central nervous system inflammation, including the regulation of a wide spectrum of inflammatory mediators, and by selectively blocking encephalitogenic T-cell reactivity. Importantly, VIP treatment was therapeutically effective in established EAE and prevented the recurrence of the disease. Consequently, VIP represents a novel multistep therapeutic approach for the future treatment of human MS.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Wang, H. Takeuchi, Y. Sonobe, S. Jin, T. Mizuno, S. Miyakawa, M. Fujiwara, Y. Nakamura, T. Kato, H. Muramatsu, et al.
Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population
PNAS, March 11, 2008; 105(10): 3915 - 3920.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E. Gonzalez-Rey, P. Anderson, and M. Delgado
Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii70 - iii76.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
L. Lajavardi, A. Bochot, S. Camelo, B. Goldenberg, M.-C. Naud, F. Behar-Cohen, E. Fattal, and Y. de Kozak
Downregulation of Endotoxin-Induced Uveitis by Intravitreal Injection of Vasoactive Intestinal Peptide Encapsulated in Liposomes
Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3230 - 3238.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology.